Compare IDEXX Laboratories, Inc. (IDXX) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs abrdn Physical Palladium Shares ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while abrdn Physical Palladium Shares ETF trades at $20.77 (market cap $586.03M). The key difference: IDEXX Laboratories, Inc. is far larger — about 69× abrdn Physical Palladium Shares ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 1,257,028). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and abrdn Physical Palladium Shares ETF for 33 Days on average.
| IDXX | PALL | |
|---|---|---|
Market Cap | $40.43B | $586.03M |
Volume | 692,164 | 1,257,028 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $766.68 | $37.18 |
52-Week Low | $504.70 | $20.30 |
Typical Hold Time | 46 Days | 33 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
PALL trades at $20.49, up 0.94% today, but technical indicators signal a bearish trend with moving averages unanimously negative. Recent news highlights palladium's underperformance versus other precious metals, with some analysts viewing current price weakness as a buying opportunity due to supply risks and industrial demand potential. Financial ratios are unavailable, limiting fundamental assessment.
The outlook remains cautious; while oversold RSI levels suggest potential for a rebound, bearish momentum dominates. Key risks include commodity price volatility and reliance on industrial demand. Investors should weigh technical weakness against contrarian bullish arguments from recent analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
